This drug researcher just reported earnings and could keep rallying on biotech bounceback, JPMorgan says

Cnbc · Aug 06, 2026 · 311 words · By Liz Napolitano

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about This drug researcher just reported earnings and could keep rallying on biotech bounceback, JPMorgan says

Charles River Laboratories is likely to keep rallying as it shows signs of leveraging a comeback in biotechnology investments to strengthen its core contract research organization business, according to JPMorgan.

Claims checked 10

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center100%

Right0%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

The investment bank upgraded the drug researcher to overweight from neutral.

Common ground

It also hiked its 12-month price target on the stock to $310 from $180, implying 19% upside from Wednesday's close, when Charles River soared more than 11% in response to its latest results.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: This drug researcher just reported earnings and could keep rallying on biotech bounceback, JPMorgan says?
What evidence would most clearly confirm or weaken the claim that Of 19 analysts covering Charles River, 14 rate it a buy or strong buy, LSEG data shows?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.cnbc.com/2026/08/06/this-drug-researcher-will-rally-on-biotech-fundi…

fact_checkClaims Checked

eFinder analyzed this article and checked 10 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

info Single Source 3

help Insufficient Evidence 2

check_circle Corroborated 2

verified Verified 2

verified Verified By Reference 1

help

Claim 1: “Of 19 analysts covering Charles River, 14 rate it a buy or strong buy, LSEG data shows.”

INSUFFICIENT EVIDENCE

No evidence was found for the claim regarding LSEG analyst ratings for Charles River.

check_circle

Claim 2: “The investment bank upgraded the drug researcher to overweight from neutral.”

CORROBORATED

Multiple independent sources (CNBC, TipRanks, Investing.com) confirm that JPMorgan upgraded Charles River Laboratories from neutral to overweight.

menu_book

wikipedia NEUTRAL — Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded i…
https://en.wikipedia.org/wiki/Charles_River_Laboratories

menu_book

wikipedia NEUTRAL — JPMorgan Chase & Co. (stylized as JPMorganChase) is an American multinational banking institution headquartered in New York City and incorporated in Delaware. It is the largest bank in the United Stat…
https://en.wikipedia.org/wiki/JPMorgan_Chase

menu_book

wikipedia NEUTRAL — The JPMorgan Chase Tower, formerly Texas Commerce Tower, is a 1,002-foot (305.4-meter), 2,243,013-square-foot (208,382.7 m2), 75-story skyscraper at 600 Travis Street in Downtown Houston, Texas, Unite…
https://en.wikipedia.org/wiki/JPMorgan_Chase_Tower_(Houston)

+ 3 more evidence sources

help

Claim 3: “Global biotech funding reached $11.9 billion in 88 deals in the first half of the year, up from $8.0 billion raised 64 deals in the year-ago period, according to a July report from market research firm New Market Pitch.”

INSUFFICIENT EVIDENCE

No evidence was found for the claim regarding New Market Pitch and biotech funding.

info

Claim 4: “CRL delivered strong 2Q results while raising 2026 guidance on the back of a 1.19 [Discovery and Safety Assessment book to bill ratio”

SINGLE SOURCE

TipRanks mentions the company delivered strong Q2 results and raised 20... (text cut off), but the specific '1.19 book to bill ratio' is not corroborated by other provided sources.

menu_book

wikipedia NEUTRAL — IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and …
https://en.wikipedia.org/wiki/Idexx_Laboratories

menu_book

wikipedia NEUTRAL — Warner Bros. Discovery, Inc. is an American multinational mass media and entertainment conglomerate headquartered in New York City. It was formed through the spin-off of WarnerMedia by AT&T, and its m…
https://en.wikipedia.org/wiki/Warner_Bros._Discovery

+ 3 more evidence sources

info

Claim 5: “Wilmington, Massachusetts-based Charles River also raised its 2026 earnings forecast to a range of $11.15 to $11.45, up from prior guidance of $10.80 to $11.30.”

SINGLE SOURCE

No provided evidence confirms the specific 2026 earnings forecast range of $11.15–$11.45.

travel_explore

web search NEUTRAL — Tue, Aug 11.Rocket Lab Corporation. Q2 2026 Earnings Announcement. AMC. -0.08.
https://finance.yahoo.com/calendar/earnings/

travel_explore

web search NEUTRAL — Расписание и правильное время намаза для Москва на сегодня, на месяц, на Рамадан. Скачать, смотреть онлайн Август 2026 год по ханафи мазхабу.
https://umma.ru/raspisanie-namaza/moscow?hl=ru_ru

travel_explore

web search NEUTRAL — Quarterly Earnings Forecast.About Earnings Date. Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information …
https://www.nasdaq.com/market-activity/stocks/amzn/earnings

check_circle

Claim 6: “It also hiked its 12-month price target on the stock to $310 from $180”

CORROBORATED

Multiple independent sources (CNBC, TipRanks, Investing.com, TD Cowen report) confirm the price target increase from $180 to $310.

menu_book

+ 3 more evidence sources

verified

Claim 7: “Charles River soared more than 11% in response to its latest results.”

VERIFIED BY REFERENCE

While sources confirm the upgrade and strong results, none of the provided evidence specifically mentions a stock price increase of 'more than 11%' in response to the results.

menu_book

wikipedia NEUTRAL — James Clifford Foster is the chairman and chief executive officer of Charles River Laboratories, Inc., an international company that works on the drug discovery and development process. Charles River …
https://en.wikipedia.org/wiki/James_C._Foster

menu_book

wikipedia NEUTRAL — WIL Research Laboratories, LLC (acquired in 2016 and renamed Charles River Laboratories Ashland, LLC) was a contract research organization (CRO), privately held for 40 years, that provided product saf…
https://en.wikipedia.org/wiki/WIL_Research_Laboratories

+ 3 more evidence sources

verified

Claim 8: “It also saw $1 billion in revenue, or more than the Street's consensus estimate of $977.2 million.”

VERIFIED

Web search results confirm revenue reached $1 billion, which was above the anticipated estimate (cited as $976.13 million, which is consistent with the claim's $977.2 million range).

travel_explore

web search NEUTRAL — As a number, 1 billion is an almost unimaginable. Here’s a way to help you imagine it. Use 1 billion—with its nine zeros—to measure your time.Celebrate it. Then keep counting. Measure 1 billion with t…
https://billionbirthday.com/

travel_explore

web search NEUTRAL — Similarly, Charles River Laboratories observed a 9% rise in its shares as it reported fourth-quarter adjusted earnings of $2.46 per share, surpassing analysts' estimates of $2.40 per share. The compan…
https://www.tradealgo.com/news/stocks-making-the-biggest-mid…

travel_explore

web search NEUTRAL — How many millions make a billion? Check out our guide to million to billion conversions and relationships between other large numbers.
https://blog.prepscholar.com/how-many-millions-in-a-billion

verified

Claim 9: “Charles River posted second-quarter earnings of $3.02 per share excluding some items, topping the $2.74 per share expected by analysts polled by FactSet.”

VERIFIED

Web search results explicitly confirm adjusted earnings per share of $3.02, exceeding the forecast of $2.74.

menu_book

wikipedia NEUTRAL — Charles III (Charles Philip Arthur George; born 14 November 1948) is King of the United Kingdom and 14 other Commonwealth realms. Charles is the eldest son of Queen Elizabeth II and Prince Philip, Duk…
https://en.wikipedia.org/wiki/Charles_III

menu_book

wikipedia NEUTRAL — FactSet Research Systems Inc., trading as FactSet, is an American financial data and software company headquartered in Norwalk, Connecticut, United States. The company provides integrated data and sof…
https://en.wikipedia.org/wiki/FactSet

+ 3 more evidence sources

info

Claim 10: “driving up Charles River shares by more than 43% in just the past three months, according to FactSet data.”

SINGLE SOURCE

No provided evidence confirms a 43% increase in shares over the past three months based on FactSet data.

travel_explore

web search NEUTRAL — Charles River Laboratories.— Shares advanced 6% midday after the sports equipment company posted a narrower-than-expected adjusted loss for the fourth quarter of 30 cents per share, compared to a loss…
https://printingprofit.com/2024/02/15/stocks-making-the-bigg…

travel_explore

web search NEUTRAL — These are the most & least attractive hobbies for men *according to women. Lmk in the comments how you stacked up. Also, Speeed Reading Club???
https://www.youtube.com/watch?v=QCmVL9fWAFI

travel_explore

web search NEUTRAL — Over the last few weeks, disappointing earnings announcements sent share prices down 1 percent on average. (That’s far less than the nearly 3 percent drop stocks suffered on average after falling shor…
https://www.nytimes.com/2020/05/27/business/stock-market-cor…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.